Related Experiment Video
Updated: Aug 19, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice
Jinhui Miao1, Min Liu1,2, Qun Zhang1
1Shanghai Institute of Biological Products, Shanghai 200051, China.
Abstract:
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and poses a substantial disease burden to infants, older adults, and immunocompromised populations. Methods: In this study, a recombinant vaccinia virus (rMVA-RSV preF) was constructed based on the modified vaccinia virus Ankara (MVA) platform by inserting a stabilized prefusion F protein gene of RSV into the MVA genome. The immunogenicity of rMVA-RSV preF and preF protein was evaluated in Balb/c mice under different vaccination regimens. Results: A heterologous prime-boost regimen, priming with rMVA-RSV preF and boosting with AS01E-adjuvanted preF protein, elicited robust cellular and humoral immune responses with a Th1 bias. This regimen significantly enhanced immunogenicity compared to homologous vaccination. Conclusions: There is a lack of data from further challenge studies to support the efficacy of the rMVA-RSV preF vaccine in terms of protection, but our findings demonstrate a favorable immunogenicity profile of the rMVA-RSV preF vaccine, supporting its further development as a promising RSV vaccine candidate.
Insights
A novel respiratory syncytial virus (RSV) vaccine candidate, rMVA-RSV preF, shows promising immunogenicity in mice. A heterologous prime-boost strategy significantly enhanced immune responses, supporting further development for RSV prevention.
Area of Science:
- Vaccinology
- Virology
- Immunology
Background:
- Respiratory syncytial virus (RSV) is a major cause of severe respiratory infections, particularly in vulnerable populations.
- Infants, older adults, and immunocompromised individuals face a significant disease burden from RSV.
- Development of effective RSV vaccines is a critical public health priority.
Purpose of the Study:
- To construct and evaluate the immunogenicity of a novel recombinant modified vaccinia virus Ankara (rMVA-RSV preF) vaccine candidate.
- To compare the immune responses induced by different vaccination regimens using rMVA-RSV preF.
- To assess the potential of rMVA-RSV preF as a promising RSV vaccine.
Main Methods:
- Construction of a recombinant vaccinia virus (rMVA-RSV preF) expressing a stabilized prefusion F protein of RSV.
- Evaluation of immunogenicity in Balb/c mice using homologous and heterologous prime-boost vaccination strategies.
- Assessment of cellular and humoral immune responses, including Th1 bias.
Main Results:
- A heterologous prime-boost regimen (rMVA-RSV preF followed by AS01E-adjuvanted preF protein) induced robust cellular and humoral immunity.
- The heterologous regimen demonstrated significantly enhanced immunogenicity compared to homologous vaccination.
- The study identified a favorable immunogenic profile for the rMVA-RSV preF vaccine candidate.
Conclusions:
- The rMVA-RSV preF vaccine candidate exhibits a promising immunogenicity profile in a mouse model.
- A heterologous prime-boost vaccination strategy enhances the immune response to RSV antigens.
- Further challenge studies are needed to confirm the protective efficacy of rMVA-RSV preF against RSV infection.
